{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:54:42Z","timestamp":1777946082900,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-016131"],"award-info":[{"award-number":["INV-016131"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-technology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Technology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.slast.2026.100409","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:00:43Z","timestamp":1773392443000},"page":"100409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Experience from an HTS campaign: Investigation of susceptibility and rescue of SARS-CoV-2 nsp3 protease assay from metal contamination"],"prefix":"10.1016","volume":"38","author":[{"given":"Irene","family":"Georgiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fraser","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-0239","authenticated-orcid":false,"given":"Sean N.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-3828","authenticated-orcid":false,"given":"David","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian H.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-9576","authenticated-orcid":false,"given":"Duncan E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.slast.2026.100409_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100721","article-title":"Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses","volume":"53","author":"Artese","year":"2020","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.slast.2026.100409_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.963701","article-title":"Druggable targets and therapeutic development for COVID-19","volume":"10","author":"Duan","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.slast.2026.100409_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104269","article-title":"Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19","volume":"104","author":"Faheem","year":"2020","journal-title":"Bioorg Chem"},{"issue":"21","key":"10.1016\/j.slast.2026.100409_bib0004","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: drug targets and potential treatments","volume":"63","author":"Gil","year":"2020","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: a systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.slast.2026.100409_bib0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Baez-Santos","year":"2015","journal-title":"Antiviral Res"},{"issue":"24","key":"10.1016\/j.slast.2026.100409_bib0007","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","article-title":"Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity","volume":"78","author":"Harcourt","year":"2004","journal-title":"J Virol"},{"issue":"24","key":"10.1016\/j.slast.2026.100409_bib0008","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","article-title":"The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity","volume":"79","author":"Barretto","year":"2005","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.slast.2026.100409_bib0009","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"18","key":"10.1016\/j.slast.2026.100409_bib0010","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J"},{"issue":"24","key":"10.1016\/j.slast.2026.100409_bib0011","doi-asserted-by":"crossref","first-page":"15199","DOI":"10.1128\/JVI.79.24.15199-15208.2005","article-title":"The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme","volume":"79","author":"Lindner","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.slast.2026.100409_bib0012","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"7835","key":"10.1016\/j.slast.2026.100409_bib0013","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"issue":"42","key":"10.1016\/j.slast.2026.100409_bib0014","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.slast.2026.100409_bib0015","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm401712t","article-title":"X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases","volume":"57","author":"Baez-Santos","year":"2014","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.slast.2026.100409_bib0016","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/jm900611t","article-title":"Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease","volume":"52","author":"Ghosh","year":"2009","journal-title":"J Med Chem"},{"issue":"13","key":"10.1016\/j.slast.2026.100409_bib0017","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm1004489","article-title":"Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation","volume":"53","author":"Ghosh","year":"2010","journal-title":"J Med Chem"},{"issue":"13","key":"10.1016\/j.slast.2026.100409_bib0018","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1080\/07391102.2020.1780946","article-title":"Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors","volume":"39","author":"Amin","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.slast.2026.100409_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.861209","article-title":"Insights into drug repurposing, as well as specificity and compound properties of piperidine-based SARS-CoV-2 PLpro inhibitors","volume":"10","author":"Calleja","year":"2022","journal-title":"Front Chem"},{"issue":"7","key":"10.1016\/j.slast.2026.100409_bib0020","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Cent Sci"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0021","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.slast.2026.100409_bib0022","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.chembiol.2021.04.020","article-title":"Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2","volume":"28","author":"Shan","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.slast.2026.100409_bib0023","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Potent, Novel SARS-CoV-2 PLpro inhibitors block viral replication in monkey and human cell cultures","volume":"65","author":"Shen","year":"2022","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.slast.2026.100409_bib0024","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity","volume":"65","author":"Shen","year":"2022","journal-title":"J Med Chem"},{"issue":"6690","key":"10.1016\/j.slast.2026.100409_bib0025","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.adm9724","article-title":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model","volume":"383","author":"Tan","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54462-0","article-title":"Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19","volume":"15","author":"Lu","year":"2024","journal-title":"Nat Commun"},{"issue":"35","key":"10.1016\/j.slast.2026.100409_bib0027","doi-asserted-by":"crossref","first-page":"eado4288","DOI":"10.1126\/sciadv.ado4288","article-title":"Discovery of SARS-CoV-2 papain-like protease (PL(pro)) inhibitors with efficacy in a murine infection model","volume":"10","author":"Garnsey","year":"2024","journal-title":"Sci Adv"},{"issue":"7","key":"10.1016\/j.slast.2026.100409_bib0028","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.apsb.2024.04.011","article-title":"Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2","volume":"14","author":"Zheng","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0029","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1038\/s41467-025-57905-4","article-title":"A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID","volume":"16","author":"Bader","year":"2025","journal-title":"Nat Commun"},{"issue":"42","key":"10.1016\/j.slast.2026.100409_bib0030","doi-asserted-by":"crossref","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci Adv"},{"issue":"10","key":"10.1016\/j.slast.2026.100409_bib0031","doi-asserted-by":"crossref","first-page":"8633","DOI":"10.3390\/ijms24108633","article-title":"Structure-based design of potent peptidomimetic inhibitors covalently targeting SARS-CoV-2 papain-like protease","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0032","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41467-023-37254-w","article-title":"Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2","volume":"14","author":"Sanders","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0033","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0034","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","volume":"11","author":"Gao","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1016\/j.slast.2026.100409_bib0035","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jpha.2020.08.012","article-title":"Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches","volume":"10","author":"Alamri","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.slast.2026.100409_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.594009","article-title":"Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease","volume":"8","author":"Delre","year":"2020","journal-title":"Front Chem"},{"key":"10.1016\/j.slast.2026.100409_bib0037","article-title":"In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease","volume":"8","author":"Huynh","year":"2020","journal-title":"Front Chem"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0038","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1021\/acs.jproteome.0c00836","article-title":"Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An In Silico Study","volume":"20","author":"Jamalan","year":"2021","journal-title":"J Proteome Res"},{"issue":"14","key":"10.1016\/j.slast.2026.100409_bib0039","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1080\/07391102.2020.1784291","article-title":"Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease","volume":"39","author":"Kandeel","year":"2021","journal-title":"J Biomol Struct Dyn"},{"issue":"2","key":"10.1016\/j.slast.2026.100409_bib0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s11224-020-01665-y","article-title":"Discovery of small molecule PLpro inhibitor against COVID-19 using structure-based virtual screening, molecular dynamics simulation, and molecular mechanics\/Generalized Born surface area (MM\/GBSA) calculation","volume":"32","author":"Pang","year":"2021","journal-title":"Struct Chem"},{"issue":"7","key":"10.1016\/j.slast.2026.100409_bib0041","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1021\/acs.jcim.2c01641","article-title":"Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors","volume":"63","author":"Garland","year":"2023","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.slast.2026.100409_bib0042","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1021\/acs.jcim.2c00693","article-title":"Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2","volume":"62","author":"Santos","year":"2022","journal-title":"J Chem Inf Model"},{"issue":"12","key":"10.1016\/j.slast.2026.100409_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33179","article-title":"Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.slast.2026.100409_bib0044","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1021\/acsinfecdis.1c00629","article-title":"Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor","volume":"8","author":"Ma","year":"2022","journal-title":"ACS Infect Dis"},{"issue":"2","key":"10.1016\/j.slast.2026.100409_bib0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors","volume":"5","author":"Ma","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"52","key":"10.1016\/j.slast.2026.100409_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202212378","article-title":"Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARS-CoV-2 Papain-Like Protease","volume":"61","author":"Hu","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"10.1016\/j.slast.2026.100409_bib0047","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s42003-022-03737-7","article-title":"Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease","volume":"5","author":"Srinivasan","year":"2022","journal-title":"Commun Biol"},{"issue":"3","key":"10.1016\/j.slast.2026.100409_bib0048","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cbpa.2010.03.020","article-title":"Apparent activity in high-throughput screening: origins of compound-dependent assay interference","volume":"14","author":"Thorne","year":"2010","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.slast.2026.100409_bib0049","series-title":"The Power of Functional Resins in Organic Synthesis","author":"Tulla-Puche","year":"2008"},{"issue":"8","key":"10.1016\/j.slast.2026.100409_bib0050","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/adsc.200404071","article-title":"The art of meeting palladium specifications in active pharmaceutical ingredients produced by Pd-catalyzed reactions","volume":"346","author":"Garrett","year":"2004","journal-title":"Adv Synth Catal"},{"issue":"2","key":"10.1016\/j.slast.2026.100409_bib0051","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/acsmedchemlett.1c00638","article-title":"Pilot Study to Quantify Palladium Impurities in Lead-like Compounds Following Commonly Used Purification Techniques","volume":"13","author":"Chatzopoulou","year":"2022","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"10.1016\/j.slast.2026.100409_bib0052","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/ml3003296","article-title":"Metal impurities cause false positives in high-throughput screening campaigns","volume":"4","author":"Hermann","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"10.1016\/j.slast.2026.100409_bib0053","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.slasd.2022.03.003","article-title":"High-throughput detection of metal contamination in HTS outputs","volume":"27","author":"Molyneux","year":"2022","journal-title":"SLAS Discov"},{"issue":"11","key":"10.1016\/j.slast.2026.100409_bib0054","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.4155\/fmc.14.60","article-title":"The essential roles of chemistry in high-throughput screening triage","volume":"6","author":"Dahlin","year":"2014","journal-title":"Future Med Chem"},{"issue":"22","key":"10.1016\/j.slast.2026.100409_bib0055","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/ja00905a001","article-title":"Hard and soft acids and bases","volume":"85","author":"Pearson","year":"1963","journal-title":"J Am Chem Soc"},{"issue":"3-4","key":"10.1016\/j.slast.2026.100409_bib0056","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0263617420918729","article-title":"Selective chelating precipitation of palladium metal from electroplating wastewater using chitosan and its derivative","volume":"38","author":"Xie","year":"2020","journal-title":"Adsorpt Sci Technol"},{"issue":"18","key":"10.1016\/j.slast.2026.100409_bib0057","doi-asserted-by":"crossref","first-page":"9461","DOI":"10.1021\/acs.inorgchem.6b01702","article-title":"A quantitative scale of oxophilicity and thiophilicity","volume":"55","author":"Kepp","year":"2016","journal-title":"Inorg Chem"},{"issue":"7519","key":"10.1016\/j.slast.2026.100409_bib0058","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemistry: chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"}],"container-title":["SLAS Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472630326000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472630326000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T15:26:49Z","timestamp":1777735609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472630326000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":58,"alternative-id":["S2472630326000221"],"URL":"https:\/\/doi.org\/10.1016\/j.slast.2026.100409","relation":{},"ISSN":["2472-6303"],"issn-type":[{"value":"2472-6303","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience from an HTS campaign: Investigation of susceptibility and rescue of SARS-CoV-2 nsp3 protease assay from metal contamination","name":"articletitle","label":"Article Title"},{"value":"SLAS Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slast.2026.100409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100409"}}